应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02335 麦科医药-B
已收盘 08-20 16:09:07
30.200
-0.400
-1.31%
最高
31.400
最低
29.900
成交量
41.88万
今开
30.640
昨收
30.600
日振幅
4.90%
总市值
100.19亿
流通市值
84.58亿
总股本
3.32亿
成交额
1,289万
换手率
0.15%
流通股本
2.80亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
港股异动 | 麦科医药-B(02335.HK)午后涨近6% 创新药XTL6001三登国际顶级学术舞台
智通财经 · 08-18 13:48
港股异动 | 麦科医药-B(02335.HK)午后涨近6% 创新药XTL6001三登国际顶级学术舞台
麦科医药-B(02335)主要产品XTL6001研究成果获EASD 2026及ASN Kidney Week 2026收录
公告速递 · 08-17
麦科医药-B(02335)主要产品XTL6001研究成果获EASD 2026及ASN Kidney Week 2026收录
麦科医药-B(02335.HK):XTL6001的研究获接纳于EASD 2026及ASN KIDNEY WEEK 2026作报告
智通财经 · 08-17
麦科医药-B(02335.HK):XTL6001的研究获接纳于EASD 2026及ASN KIDNEY WEEK 2026作报告
麦科医药-B(02335.HK)8月28日举行董事会会议批准中期业绩
中金财经 · 08-14
麦科医药-B(02335.HK)8月28日举行董事会会议批准中期业绩
麦科医药-B(02335)拟于8月28日召开董事会 审议2026年中期业绩及派息方案
公告速递 · 08-14
麦科医药-B(02335)拟于8月28日召开董事会 审议2026年中期业绩及派息方案
港股异动 | 麦科医药-B(02335)涨超3% MT200605临床前及I期临床数据获接纳于WSC 2026大会作口头报告
智通财经 · 08-11
港股异动 | 麦科医药-B(02335)涨超3% MT200605临床前及I期临床数据获接纳于WSC 2026大会作口头报告
麦科医药-B:MT200605 临床前及I期临床数据将于世界卒中大会口头发表
财中社 · 08-11
麦科医药-B:MT200605 临床前及I期临床数据将于世界卒中大会口头发表
麦科医药-B(02335.HK):MT200605的临床前及I期临床数据获接纳于2026年第十八届世界卒中大会作口头报告
智通财经 · 08-10
麦科医药-B(02335.HK):MT200605的临床前及I期临床数据获接纳于2026年第十八届世界卒中大会作口头报告
麦科医药脑梗创新药II期临床达主要终点,对标数十亿元市场
21财经 · 08-04
麦科医药脑梗创新药II期临床达主要终点,对标数十亿元市场
麦科医药-B 2026年7月无新增发行或股份变动
公告速递 · 08-04
麦科医药-B 2026年7月无新增发行或股份变动
港股异动 | 麦科医药-B(02335)涨超3% MT200605治疗急性缺血性脑卒中的II期临床试验达到主要终点
智通财经 · 08-04
港股异动 | 麦科医药-B(02335)涨超3% MT200605治疗急性缺血性脑卒中的II期临床试验达到主要终点
麦科医药-B(02335.HK):MT200605治疗急性缺血性脑卒中(AIS)的II期临床试验达到主要终点
智通财经 · 08-03
麦科医药-B(02335.HK):MT200605治疗急性缺血性脑卒中(AIS)的II期临床试验达到主要终点
麦科医药-B:MT200605治疗急性缺血性脑卒中II期临床试验达到主要终点
公告速递 · 08-03
麦科医药-B:MT200605治疗急性缺血性脑卒中II期临床试验达到主要终点
陕西麦科医药-B:MT200605治疗急性缺血性脑卒中II期临床试验达主要终点,结果显著
美股速递 · 08-03
陕西麦科医药-B:MT200605治疗急性缺血性脑卒中II期临床试验达主要终点,结果显著
一周港股牛熊榜 | 基本半导体飙近42%,股价创上市以来新高;迅策累涨近34%,TokenOS加速商业场景落地;卓越睿新本周大幅回调逾25%
老虎资讯综合 · 07-25
一周港股牛熊榜 | 基本半导体飙近42%,股价创上市以来新高;迅策累涨近34%,TokenOS加速商业场景落地;卓越睿新本周大幅回调逾25%
麦科医药-B(02335)自主研发神经保护剂MT200605完成急性缺血性脑卒中II期临床数据库锁定
公告速递 · 07-24
麦科医药-B(02335)自主研发神经保护剂MT200605完成急性缺血性脑卒中II期临床数据库锁定
麦科医药-B(02335):MT200605用于急性缺血性脑卒中(AIS)的II期临床试验完成数据库锁定
智通财经 · 07-24
麦科医药-B(02335):MT200605用于急性缺血性脑卒中(AIS)的II期临床试验完成数据库锁定
【IPO前哨】溶瘤病毒先驱亦诺微赴港:核心团队“顶配”,三年亏超15亿
港股解码 · 07-20
【IPO前哨】溶瘤病毒先驱亦诺微赴港:核心团队“顶配”,三年亏超15亿
麦科医药-B发布自愿性公告
证券日报 · 07-11
麦科医药-B发布自愿性公告
麦科医药-B(02335.HK):MT1002用于血液透析患者抗凝的II期临床试验完成首例患者入组
智通财经 · 07-09
麦科医药-B(02335.HK):MT1002用于血液透析患者抗凝的II期临床试验完成首例患者入组
加载更多
公司概况
公司名称:
麦科医药-B
所属市场:
SEHK
上市日期:
--
主营业务:
陕西麦科奥特医药科技股份有限公司(以下简称“麦科奥特”)于2007年1月在西安成立,现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业,致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业,聚焦于心脑血管、代谢性疾病、炎症疼痛相关疾病新药的研发。公司致力于创制新药、挽救生命,满足未被满足的临床需求,用科技创新为人类健康保驾护航。 麦科奥特作为一家平台型生物技术公司,致力于加速全球新一代双特异性/多特异性多肽药物的创新及开发,我们的核心产品处于Ⅲ期临床试验。自2007年成立以来,我们专注于代谢性疾病(尤其是肾脏相关疾病)以及心脑血管疾病,作为提出双/多特异性肽技术概念的全球先驱,并凭借进入临床开发的广泛候选产品管线,我们已在该领域确立领先地位。
发行价格:
--
{"stockData":{"symbol":"02335","market":"HK","secType":"STK","nameCN":"麦科医药-B","latestPrice":30.2,"timestamp":1787213347756,"preClose":30.6,"halted":0,"volume":418800,"delay":0,"changeRate":-0.013071895424836671,"floatShares":280071100,"shares":331740350,"eps":0,"marketStatus":"已收盘","change":-0.4,"latestTime":"08-20 16:09:07","open":30.64,"high":31.4,"low":29.9,"amount":12893388,"amplitude":0.04902,"askPrice":30.52,"askSize":17800,"bidPrice":30.2,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-0.609,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"listingDate":1782230400000,"exchange":"SEHK","adjPreClose":30.6,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":0.975314,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02335","defaultTab":"news","newsList":[{"id":"2660454447","title":"港股异动 | 麦科医药-B(02335.HK)午后涨近6% 创新药XTL6001三登国际顶级学术舞台","url":"https://stock-news.laohu8.com/highlight/detail?id=2660454447","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660454447?lang=zh_cn&edition=full","pubTime":"2026-08-18 13:48","pubTimestamp":1787032087,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1574","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107177771","title":"麦科医药-B(02335)主要产品XTL6001研究成果获EASD 2026及ASN Kidney Week 2026收录","url":"https://stock-news.laohu8.com/highlight/detail?id=1107177771","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107177771?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:45","pubTimestamp":1786963544,"startTime":"0","endTime":"0","summary":"麦科医药-B8月17日发布自愿性公告称,集团关键产品XTL6001的最新研究成果已获多项国际学术会议接纳并将作报告。EASD 2026将于2026年9月28日至10月2日在意大利米兰举行。此外,集团核心产品MT1013的相关研究成果曾获选于ASN Kidney Week 2025的Late-Breaking Research Posters环节展示。公司表示,XTL6001连续入选ADA、EASD及ASN等国际学术会议,标志着其在体重管理及肾脏病领域的研发进展迈出重要一步。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481420","title":"麦科医药-B(02335.HK):XTL6001的研究获接纳于EASD 2026及ASN KIDNEY WEEK 2026作报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660481420?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:40","pubTimestamp":1786963221,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147209","title":"麦科医药-B(02335.HK)8月28日举行董事会会议批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147209","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659147209?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:27","pubTimestamp":1786717626,"startTime":"0","endTime":"0","summary":"格隆汇8月14日丨麦科医药-B(02335.HK)宣布,公司将于2026年8月28日(星期五)举行董事会会议,藉以(其中包括)批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布,考虑派发中期股息的建议(如有),以及处理其他事项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260814/32335962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124062847","title":"麦科医药-B(02335)拟于8月28日召开董事会 审议2026年中期业绩及派息方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1124062847","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124062847?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:45","pubTimestamp":1786715131,"startTime":"0","endTime":"0","summary":"陕西麦科奥特医药科技股份有限公司(02335)8月14日公告称,公司董事会将于2026年8月28日(星期五)召开会议,主要议程包括:一、审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布;二、考虑派发中期股息的建议(如有);三、处理其他事项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658896964","title":"港股异动 | 麦科医药-B(02335)涨超3% MT200605临床前及I期临床数据获接纳于WSC 2026大会作口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2658896964","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658896964?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:39","pubTimestamp":1786419558,"startTime":"0","endTime":"0","summary":"消息面上,8月10日,麦科医药-B发布公告,本集团自主研发的用于治疗急性缺血性脑卒中的注射用神经保护候选药物MT200605的临床前及I期临床数据,已获接纳于2026年第十八届世界卒中大会作口头报告。在MT200605的临床前及I期临床数据获接纳于WSC 2026上作口头报告的同时,MT200605用于急性缺血性脑卒中的II期临床试验已获得具有统计学意义及临床相关性的结果,并达到主要终点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1815336091.USD","LU1878469433.USD","VXUS","LU0757428866.USD","BK4129","BK4585","02335","BK4588","WSC","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196396","title":"麦科医药-B:MT200605 临床前及I期临床数据将于世界卒中大会口头发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196396","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658196396?lang=zh_cn&edition=full","pubTime":"2026-08-11 08:57","pubTimestamp":1786409820,"startTime":"0","endTime":"0","summary":"8月10日,麦科医药-B(02335)发布公告,公司自主研发的用于治疗急性缺血性脑卒中的注射用神经保护候选药物MT200605的临床前及I期临床数据,已获接纳于2026年第十八届世界卒中大会作口头报告。该大会将于2026年10月21日至23日在韩国首尔举行,报告时间为10月21日上午8时至9时30分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837365795.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837365795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658937540","title":"麦科医药-B(02335.HK):MT200605的临床前及I期临床数据获接纳于2026年第十八届世界卒中大会作口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2658937540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658937540?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:56","pubTimestamp":1786373772,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158417515","title":"麦科医药脑梗创新药II期临床达主要终点,对标数十亿元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1158417515","media":"21财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158417515?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:43","pubTimestamp":1785836628,"startTime":"0","endTime":"0","summary":"8月3日晚,麦科医药发布自愿性公告,宣布其自主研发的注射用神经保护候选药物MT200605在治疗急性缺血性脑卒中的II期临床试验中成功达到主要研究终点。截至目前,麦科已有7条管线进入临床,是国内进入临床试验阶段数量最多的多肽创新药企业。据麦科医药介绍,MT200605为自研创新药,通过静脉注射抵达脑组织内部。截至麦科医药上市,共有三种神经保护药物获国家药监局批准。根据公告,此次达到主要终点的II期临床试验共入组360名受试者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"lsy1653463924952","url":"https://m.21jingji.com/article/20260804/herald/796fe5d0c1bcc58369f83b0c12f3a89f_zaker.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://m.21jingji.com/article/20260804/herald/796fe5d0c1bcc58369f83b0c12f3a89f_zaker.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1653463924952","symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153660594","title":"麦科医药-B 2026年7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1153660594","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153660594?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:58","pubTimestamp":1785833884,"startTime":"0","endTime":"0","summary":"陝西麥科奧特醫藥科技股份有限公司于2026年8月4日发布2026年7月股份变动月报表,报告期为截至2026年7月31日。公司注册股本合计为6,634,807元人民币。报告期内,公司及其库藏股数量均未发生变动,H股及内资股发行量分别保持280,071,100股和51,669,250股不变,合计331,740,350股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656401580","title":"港股异动 | 麦科医药-B(02335)涨超3% MT200605治疗急性缺血性脑卒中的II期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2656401580","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656401580?lang=zh_cn&edition=full","pubTime":"2026-08-04 14:38","pubTimestamp":1785825519,"startTime":"0","endTime":"0","summary":"消息面上,8月3日,麦科医药-B发布公告,本集团自主研发的用于治疗AIS的候选药物MT200605的II期临床试验已获得顶线数据。数据显示,该临床试验已达到其主要研究终点,结果具有统计学显著性及临床意义。除用于治疗急性缺血性脑卒中外,MT200605亦正开发用于治疗亨廷顿舞蹈病。MT200605可选择性激活TrkB 信号通路,同时发挥神经保护及抗氧化双重作用,以保护神经组织的结构及功能。于2026年3月, MT200605针对HD适应症正式获得美国食品药品监督管理局孤儿药认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","02335","MDTX","BK4588","VXUS","BK1161","BMED","KCAI","BK4585","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656937036","title":"麦科医药-B(02335.HK):MT200605治疗急性缺血性脑卒中(AIS)的II期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2656937036","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656937036?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:56","pubTimestamp":1785768982,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156750839","title":"麦科医药-B:MT200605治疗急性缺血性脑卒中II期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1156750839","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156750839?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:56","pubTimestamp":1785768963,"startTime":"0","endTime":"0","summary":"陝西麥科奧特醫藥科技股份有限公司8月3日公布,自主研发的候选药物MT200605用于治疗急性缺血性脑卒中的II期临床试验已获得顶线数据,并达到主要研究终点。该试验为多中心、随机、双盲、安慰剂对照设计,共入组360名受试者。安全性方面,MT200605整体耐受性良好。麦科医药-B表示,此次公告属自愿披露,旨在让投资者了解公司最新业务进展,不构成对任何药物或治疗手段的推广。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184553111","title":"陕西麦科医药-B:MT200605治疗急性缺血性脑卒中II期临床试验达主要终点,结果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1184553111","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184553111?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:54","pubTimestamp":1785768851,"startTime":"0","endTime":"0","summary":"陕西麦科医药-B(MICOT PHARMA-B)宣布,其研发的MT200605在针对急性缺血性脑卒中(AIS)的II期临床试验中,已成功达成主要终点。该试验结果具备统计学显著意义,为这一候选药物的后续开发奠定了关键基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194444261","title":"一周港股牛熊榜 | 基本半导体飙近42%,股价创上市以来新高;迅策累涨近34%,TokenOS加速商业场景落地;卓越睿新本周大幅回调逾25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194444261","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194444261?lang=zh_cn&edition=full","pubTime":"2026-07-25 08:41","pubTimestamp":1784940109,"startTime":"0","endTime":"0","summary":"迅策本周累计上涨33.92%,TokenOS加速商业场景落地,中长期估值天花板有望打开消息面上,近日,迅策科技宣布其与洪泰基金母公司青岛鑫宸科创实业有限公司正式达成全面战略合作。此次合作,标志着迅策科技TokenOS数据Token化能力首次进入私募股权投资领域。","market":"hk","thumbnail":"https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02687","02589","02706","02768","02335","03317","02630","06809","09971","00290"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131710682","title":"麦科医药-B(02335)自主研发神经保护剂MT200605完成急性缺血性脑卒中II期临床数据库锁定","url":"https://stock-news.laohu8.com/highlight/detail?id=1131710682","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131710682?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:45","pubTimestamp":1784893532,"startTime":"0","endTime":"0","summary":"7月24日,麦科医药-B公告称,其自主研发的候选药物MT200605用于急性缺血性脑卒中的II期临床试验已完成数据库锁定。该试验为多中心、随机、双盲、安慰剂对照研究,旨在评估MT200605的疗效、安全性及药代动力学特征。近期,试验数据已全部封库,为后续统计分析奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653081228","title":"麦科医药-B(02335):MT200605用于急性缺血性脑卒中(AIS)的II期临床试验完成数据库锁定","url":"https://stock-news.laohu8.com/highlight/detail?id=2653081228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653081228?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:43","pubTimestamp":1784893418,"startTime":"0","endTime":"0","summary":"智通财经APP讯,麦科医药-B 发布公告,集团自主研发的用于治疗急性缺血性脑卒中的候选药物MT200605的II期临床试验已完成数据库锁定。在中国进行的MT200605用于急性缺血性脑卒中的II期临床试验为一项多中心、随机、双盲、安慰剂对照的试验,旨在评价MT200605的疗效、安全性及药代动力学。该II期临床试验于2025年9月完成首例患者入组,于2026年3月完成全部360例患者入组,于2026年6月完成最后一例患者出组,并于近期完成数据库锁定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","PSYK","02335","IBBJ","BK1161","IBBQ","AIS","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653781363","title":"【IPO前哨】溶瘤病毒先驱亦诺微赴港:核心团队“顶配”,三年亏超15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2653781363","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653781363?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:56","pubTimestamp":1784534160,"startTime":"0","endTime":"0","summary":"截至2026年7月7日,公司研发管线拥有两款针对实体瘤的溶瘤免疫疗法产品。招股书披露,亦诺微医药至今没有任何产品销售收入,全部收入来自对外授权和合作安排。本次IPO不仅是公司拓宽融资渠道、支撑全球临床开发的融资窗口,更是市场对“溶瘤病毒+外泌体双商业模式”价值的一次集中定价考验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650513680&idx=2&sn=58ffec752dc2276dd3ddb53f575c7989&chksm=f260d47fc5175d696c888ae87f2d3f1146b6fb45b54c0e147a564e3b884e9ff4523f0b6608f2#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1515","BK1574","02697","BK1161","09939","02335","BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650553431","title":"麦科医药-B发布自愿性公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2650553431","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650553431?lang=zh_cn&edition=full","pubTime":"2026-07-11 12:02","pubTimestamp":1783742520,"startTime":"0","endTime":"0","summary":"近日,陕西麦科奥特医药科技股份有限公司(以下简称“麦科医药-B”)发布自愿性公告,宣布其自主研发的候选药物MT1002,用于血液透析患者抗凝的Ⅱ期临床研究,近日已成功完成首例患者入组,标志着该临床研究已正式迈入实质性执行阶段。据了解,慢性肾脏病(CKD)是由长期肾实质疾病引起的进行性肾小球功能丧失。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607113802467089.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607113802467089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650192510","title":"麦科医药-B(02335.HK):MT1002用于血液透析患者抗凝的II期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2650192510","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650192510?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:46","pubTimestamp":1783594007,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.micot.cn","stockEarnings":[{"period":"1week","weight":0.0248},{"period":"1month","weight":-0.138},{"period":"3month","weight":0.6813},{"period":"ytd","weight":0.6813}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"陕西麦科奥特医药科技股份有限公司(以下简称“麦科奥特”)于2007年1月在西安成立,现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业,致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业,聚焦于心脑血管、代谢性疾病、炎症疼痛相关疾病新药的研发。公司致力于创制新药、挽救生命,满足未被满足的临床需求,用科技创新为人类健康保驾护航。\n麦科奥特作为一家平台型生物技术公司,致力于加速全球新一代双特异性/多特异性多肽药物的创新及开发,我们的核心产品处于Ⅲ期临床试验。自2007年成立以来,我们专注于代谢性疾病(尤其是肾脏相关疾病)以及心脑血管疾病,作为提出双/多特异性肽技术概念的全球先驱,并凭借进入临床开发的广泛候选产品管线,我们已在该领域确立领先地位。","exchange":"SEHK","name":"麦科医药-B","nameEN":"MICOT PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"麦科医药-B,02335,麦科医药-B股票,麦科医药-B股票老虎,麦科医药-B股票老虎国际,麦科医药-B行情,麦科医药-B股票行情,麦科医药-B股价,麦科医药-B股市,麦科医药-B股票价格,麦科医药-B股票交易,麦科医药-B股票购买,麦科医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}